Treatment of acute promyelocytic leukaemia

Best Practice and Research: Clinical Haematology

Volumn 14, Issue 1, 2001, Pages 153-174

  Fenaux, Pierre ^a   Chomienne, Christine ^b   Degos, Laurent ^b  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b SAINT LOUIS HOSPITAL   (France)

Author keywords

Acute promyelocytic leukemia; All trans retinotic acid; Arsenic; Chemotherapy

Indexed keywords

AMINOTRANSFERASE; AMSACRINE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BCR ABL PROTEIN; CORTICOSTEROID; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; ETOPOSIDE; ISOPROTEIN; METHOTREXATE; RETINOIC ACID; TIOGUANINE; TRIACYLGLYCEROL;

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ACUTE MYELOBLASTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; APOPTOSIS; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BASOPHILIA; BLAST CELL; BLOOD CLOTTING DISORDER; BONE MARROW NECROSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CELL STRUCTURE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; ERYTHEMA NODOSUM; FATALITY; FOURNIER GANGRENE; HEADACHE; HUMAN; HYPERCALCEMIA; HYPERTRIGLYCERIDEMIA; INCIDENCE; LEUKOCYTE COUNT; LEUKOCYTOSIS; MAINTENANCE THERAPY; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY; MYOSITIS; NECROTIZING ARTERITIS; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTE; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RETINOIC ACID SYNDROME; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; THROMBOCYTOSIS; THROMBOSIS; TREATMENT FAILURE; XEROSTOMIA;

EID: 0035032653     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1053/beha.2000.0121     Document Type: Article

References (127)

1. Proposals for the classification of the acute leukemias
2. A variant form of hypergranular promyelocytic leukemia (M3)
3. Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia
4. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR
5. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML
6. Coagulation disorders associated with acute promyelocytic leukemia: Corrective effect of all-trans retinoic acid treatment
7. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia
8. Treatment of acute promyelocytic leukaemia
9. Acute promyelocytic leukemia. Results of treatment with daunorubicin
10. Is heparin administration necessary during induction chemotherapy for patients with acute promyelocytic leukemia?
11. Beneficial effect of heparin in the management of patients with APL
12. Acute promyelocytic leukemia. Therapy results prognostic factors
13. Acute promyelocytic leukemia: Treatment results during a decade at Memorial Hospital
14. Treatment of acute promyelocytic leukemia: A report on 70 cases
15. Leucémie aiguë promyélocytaire: Étude rétrospective de 119 malades traités par daunorubicine
16. Aggressive daunomycin (DNR) therapy improves survival in acute promyelocytic leukemia (APL), a Southwest Oncology Group (SWOG trial)
17. Idarubicin treatment of acute promyelocytic leukemia: The Gimema experience
18. A randomized trial of amacrine and rubidazone in 39 patients with acute promyelocytic leukemia
19. Primary therapy of acute promyelocytic leukemia: Role of amsacrine and daunorubicin based therapy
20. Effect of high dose AraCX in APL
21. Short-term treatment for adult hypergranular and microgranular acute promyelocytic lekemia
22. The thrombophilic state in acute promyelocytic leukemia
23. Acute promyelocytic leukemia in 57 previously untreated patients
24. Acute promyelocytic leukemia. MD Anderson hospital experience
25. Use of all trans retinoic acid in the treatment of acute promyelocytic leukemia
26. All trans retinoic acid as a differentiating therapy for acute promyelocytic leukemia. I. Clinical results
27. Treatment of first relapse in acute promyelocytic leukaemia with all trans retinoic acid
28. A clinical and experimental study on all trans retinoic acid treated acute promyelocytic leukemia patients
29. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all trans retinoic acid)
30. All trans retinoic acid in promyelocytic leukemias. II. In vitro studies structure function relationship
31. Proof of differentiating mode of action all-trans retinoic acid in acute promyelocytic leukemia using X-linked clonal analysis
32. Remission induction of acute promyelocytic leukemia by all-trans-retinoic acid: Molecular evidence of restoration of normal hematopoiesis after differentiation and subsequent extinction of leukemic clone
33. All-trans retinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: A pilot study on 26 cases
34. The 'retinoic acid syndrome' in acute promyelocytic leukemia
35. Treatment of acute promyelocytic leukemia with all-trans retinoic acid: An update of the New York experience
36. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia
37. Effect of all trans retinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial
38. Prolonged follow up confirms that all trans retinoic acid (ATRA) followed by chemotherapy reduces the risk of relapse in newly diagnosed acute promyelocytic leukemia (APL)
39. Long term follow up confirms the benefit of all transretinoic acid in acute promyelocytic leukemia
40. All trans-retinoic acid in acute promyelocytic leukemia
41. A randomized comparison of ATRA followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance treatment in APL
42. Morbidity and costs of remission induction therapy with all-trans retinoic acid compared with standard chemotherapy in acute promyelocytic leukemia
43. Outpatient management of acute promyelocytic leukemia after consolidation chemotherapy
44. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: Result of the randomized MRC Trial
45. Incidence, clinical features, and outcome of all-trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia
46. Effectiveness and pharmacokinetics of low-dose all-trans retinoic acid (25 mg/m2) in acute promyelocytic leukemia
47. Tretinoin toxicity in children with acute promyelocytic leukaemia
48. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxocity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia
49. Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine
50. Induction of retinoic acid-binding protein in normal and malignant human myeloid cells by retinoic acid in acute promyelocytic leukemia patients
51. Continuous treatment with all-trans RA progressively decreases plasma drug concentrations: Implications for relapse and resistance in acute promyelocytic leukemia
52. Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia
53. Pharmacokinetics of all-trans-retinoic acid administered on an intermittent schedule
54. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy
55. Correlation of CD2 expression with PML gene breakpoints in patients with acute promyelocytic leukemia
56. The immunophenotype of acute promyelocytic leukemia (APL): An ECOG study
57. Immunophenotype of adult and childhood acute promyelocytic leukaemia: Correlation with morphology, type of PML gene breakpoint and clinical outcome. A cooperative Italian study on 196 cases
58. CD 56 expression in acute promyelocytic leukemia: A possible indicator of poor treatment outcome?
59. Association of PML-RARalpha fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: An intergroup molecular study
60. Molecular analysis and clinical outcome of adult APL patients with the type V PML-RARalpha isoform: Results from intergroup protocol 0129
61. Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;7) translocations using real-time RT-PCR
62. Molecular monitoring of the myl/retinoic acid receptor alpha fusion gene in acute promyelocytic leukemia by polymerase chain reaction
63. A PML/RARα fusion transcript is constantly detected by RNA-based polymerase chain reaction in acute promyelocytic leukemia
64. Monitoring of treatment outcome in acute promyelocytic leukemia by RT-PCR
65. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML-RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the trial. GIMEMA-AIEOP multicenter 'AIDA' Trial
66. Molecular remission in PML/RARalpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy
67. Preliminary experience in external quality control of RT-PCR PML-RAR alpha detection in promyelocytic leukemia
68. Extramedullary involvement in patients with acute promyelocytic leukemia: A report of seven cases
69. Aucte promyelocytic leukemia relapse in the central nervous system during hematologic and molecular remission
70. Central nervous system involvement in acute promyelocytic leukemia. A description of two cases and review of the literature
71. Extramedullary disease in acute promyelocytic leukemia
72. All-trans retinoic acid for acute promyelocytic leukemia. Results of the New York study
73. Resistance to all-trans retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: Study of in vitro ATRa sensitivity and cellular retinoic acid binding protein levels in leukemic cells
74. Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation
75. Leukemic cellular retinoic acid resistance and missense mutations in the PML-RARalpha fusion after relapse of acute promyelocytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapy
76. Mutations in the E-domain of RAR portion of the PML/RAR chimeric gene may confer clinical resistance to all-trans retinoic acid in acute promyelocytic leukemia
77. Liposome encapsulation circumvents the hepatic clearance mechanisms of all-trans-retinoic acid
78. Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed promyelocytic leukemia
79. Clinical study of 9-cis retinoic acid (LGD 1057) in acute promyelocytic leukemia
80. Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid
81. Relapsed acute promyelocytic leukemia previously treated with all-trans retinoic acid: Clinical experience with a new synthetic retinoid, AM-80
82. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase
83. In vivo treatment of human acute promyelocytic leukemia with a histone deacetylase inhibitor, FR9011228
84. Molecular remission with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia
85. Study on anti-leukemic effect of tanshinone IIA in vitro and in vivo to acute promyelocytic leukemia
86. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients
87. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide
88. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: Remission induction, follow-up, and molecular monitoring in II newly diagnosed and 47 relapsed acute promyelocytic leukemia patients
89. Clinical observation on arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia
90. Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukaemia
91. Complete atrioventricular block after arsenic trioxide treatment in an acute promyelocytic leukemia patient
92. U.S. multicenter trial of arsenic trioxide (at) in acute promyelocytic leukemia (APL)
93. 3) exerts dose-dependent dual effects on APL cells
94. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway
95. Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells
96. Combined retinoic acid and arsenic therapy sharply enhances survival in a mouse apl model
97. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome
98. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: Impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid
99. Extramedullary relapse after all-trans retinoic acid treatment in acute promyelocytic leukemia-the occurrence of retinoic acid syndrome is a risk factor
100. Hematopoietic growth factor expression and ATRA sensitivity in acute promyelocytic blast cells
101. Modulation of 11-6 and 11-1β and G-CSF secretion by all trans retinoic acid in acute promyelocytic leukemia
102. Retinoic acid induces aggregation of the acute promyelocytic leukemia cell line NB-4 by utilization of LFA-I and ICAM-2
103. Pro-treatment with all-trans retinoic acid accelerates polymorpho-nuclear recovery after chemotherapy in patients with acute promyelocytic leukemia
104. Acute promyelocytic leukemia
105. Induction of differentiation of promyelocytic NB4 cells by retinoic acid is associated with rapid increase in urokinase activity subsequently down regulated by production of inhibitors
106. Multiple thrombosis in acute promyelocytic leukaemia after tretinoin
107. Fatal thromboembolism in acute promyelocytic leukemia during all-trans retinoic acid therapy combined with antifibrinolytic therapy for prophylaxis of hemorrhage
108. Coronaric thrombotic events in acute promyelocytic leukemia during all-trans retinoic acid treatment: A role for adhesion molecules overexpression?
109. Bone marrow necrosis following all-trans retinoic acid therapy for acute promyelocytic leukaemia
110. Hypercalcaemia due to all-trans retinoic acid
111. Erythema nodosum associated with all-trans-retinoic acid in the treatment of acute promyelocytic leukemia
112. Brief report: Severe symptoms of hyperhistaminemia after the treatment of acute promyelocytic leukemia with tretinoin (all trans retinoic acid)
113. Marked basophilia in acute promyelocytic leukaemia treated with all-trans retinoic acid: Molecular analysis of the cell origin of the basophilis
114. Myositis with tretinoin
115. All-trans retinoic acid treatment and Sweet syndrome
116. Sweet's syndrome during treatment with all-trans retinoic acid in a patient with acute promyelocytic leukemia
117. Fournier's gangrene during induction treatment of acute promyelocytic leukemia, a case report
118. Scrotal ulcer occurring in patients with acute promyelocytic leukemia during treatment with all-trans retinoic acid
119. All-trans retinoic acid induced thrombocytosis in a patient with acute promyelocytic leukaemia
120. All trans retinoic acid as the possible cause of necrotizing vasculitis
121. Therapy of molecular relapse in acute promyelocytic leukemia
122. 4), a monoinstitutional study
123. Two cases of extramedullary acute promyelocytic leukemia. Cytogenetics, molecular biology, and phenotypic and clinical studies
124. Persistence of retinoic acid sensitivity in relapsed acute promyelocytic leukemia with extramedullary involvement
125. Role of maintenance chemotherapy in acute promyelocytic leukemia
126. Tretinoin with chemotherapy in newly diagnosed acute promyelocytic leukaemia
127. Time course of induction of metabolism of all trans retinoic acid and the up regulation of cellular retinoic acid binding protein